I'm not saying that Satri-Cell is a direct competitor to CHMs CDH17 asset per se. Quite the opposite - there are a lot similarities to CHMs CDH17 and a number of important differences (which I outlined in my previous post).
However, I think it is important to note that CART in a gastric cancer setting is producing strong results such that the FDA is designating RMAT status which is a step above "break through" designation based on preliminary Phase 1 data. In my view, this significantly de-risks the CDH17 construct and approach, which is awesome news!
CHMs 3rd gen CDH17 preclinical data is compelling - it completely eradicated the cancer in mice in 7 cancer models (eg. colorectal, pancreatic, gastric) with no relapse and no signs of toxicity. This is far superior to Satri-Cel pre clinical!
Hope this makes sense.
CHM Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)